Datamonitor, April 2009, Pages: 156
Novel vaccine administration technologies have the potential to improve vaccine developers commercial competitiveness and to increase vaccination safety and convenience. This report assesses key
Venture Planning Group, Nov 2011, Pages: 1900
- Blood Banking Consideration
c. Vaccines and Drugs
- Antiviral Drugs
- Vaccines Against HIV
-- Transmission of HIV in Blood Products
-- HIV Transmission in Transplant and
Artificial Insemination Recipients
Venture Planning Group, April 2010, Pages: 983
. Vaccines and Drugs
18. Creutzfeldt-Jakob’s Disease
a. Background
- Blood Transmission
b. Diagnostic Tests
- Major Commercial and Academic Players
- Bayer
- Disease Sciences/Bio Tec Global
- Imperial College
Food Technology Intelligence, June 2008
You already know that concerns over pathogenic bacteria and food safety are becoming increasingly significant health issues for the public and for the food industry as well. In many countries
Global Industry Analysts, Inc., Sep 2011, Pages: 126
for Commercialization of
Therapeutic Vaccines 53
Gambro AB Enters into a Partnership with Sangart 53
WakeMed Awards a Contract
Woodhead Publishing Ltd, July 2009, Pages: 1232
- discusses key health issues, including advances in disease diagnosis, vaccine development and other emerging methods to control pathogens in aquaculture
- examines the design of a range of aquaculture
Global Industry Analysts, Inc., Sep 2010, Pages: 94
for Commercialization of
Therapeutic Vaccines 42
Gambro AB Enters into a Partnership with Sangart 42
WakeMed Awards a Contract
John Wiley and Sons Ltd, Oct 2011, Pages: 376
use of fungal enzymes and fungal proteomics, and fungal diseases of humans, antifungal agents for use in human therapy and fungal pathogens of plants. List of Contributors
1 Introduction to Fungal
Knowledge Press, July 2008, Pages: 400
-causing influenza strains. The system, SAFE: Sequencing for Avian Flu Epidemic, first uses real time RT-PCR to detect H5, the highly pathogenic avian influenza most likely to cause a pandemic. We next use
Frost & Sullivan, Dec 2002
, vaccines, and therapeutics against anthrax, smallpox, and other potential bioterror agents. Many of these technologies, particularly those designed to guard against an attack on the nation's infrastructure
